Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted For PF614-MPAR
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences has announced that the FDA has granted Breakthrough Therapy Designation for its product PF614-MPAR, which is a significant regulatory milestone that could expedite the development and review process for this potential treatment.
January 23, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ensysce Biosciences' PF614-MPAR has received FDA Breakthrough Therapy Designation, which is expected to positively influence the company's stock as it may accelerate the product's development and review process.
The FDA's Breakthrough Therapy Designation is a positive regulatory development that typically results in increased investor confidence and can lead to a rise in stock price due to the potential for accelerated approval and market entry of the drug.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100